Downloads: 1
243 lines (242 with data), 7.7 kB
T1 Age 15 25 4-year-old T2 Sex 26 29 boy T3 Disease_disorder 55 68 Blau syndrome E1 Disease_disorder:T3 T4 Disease_disorder 142 151 arthritis E2 Disease_disorder:T4 T5 Biological_structure 126 131 ankle T6 Biological_structure 136 141 wrist T7 Disease_disorder 152 165 tenosynovitis E3 Disease_disorder:T7 T8 Sign_symptom 186 190 rash E4 Sign_symptom:T8 T9 Biological_attribute 175 185 eczematous T10 Detailed_description 167 174 diffuse R1 MODIFY Arg1:T10 Arg2:E4 R2 MODIFY Arg1:T9 Arg2:E4 T11 Disease_disorder 196 203 uveitis E5 Disease_disorder:T11 T12 Disease_disorder 242 252 granulomas E6 Disease_disorder:T12 T13 Detailed_description 229 241 noncaseating R3 MODIFY Arg1:T13 Arg2:E6 T14 Diagnostic_procedure 273 286 NOD2 mutation E7 Diagnostic_procedure:T14 T15 Detailed_description 260 272 heterozygous R4 MODIFY Arg1:T15 Arg2:E7 T16 Diagnostic_procedure 288 295 p.R334W E8 Diagnostic_procedure:T16 R5 IDENTICAL Arg1:E8 Arg2:E7 T17 Medication 362 377 corticosteroids E9 Medication:T17 T18 Administration 345 352 topical T19 Administration 357 361 oral R6 MODIFY Arg1:T19 Arg2:E9 R7 MODIFY Arg1:T18 Arg2:E9 T20 Duration 383 397 over the years E10 Duration:T20 T21 Disease_disorder 398 415 visual impairment E11 Disease_disorder:T21 T22 Detailed_description 416 426 progressed R8 MODIFY Arg1:T22 Arg2:E11 A1 TREND E11 INC T23 Disease_disorder 298 316 Ocular involvement E12 Disease_disorder:T23 T24 Detailed_description 331 341 controlled R9 MODIFY Arg1:E9 Arg2:T24 R10 MODIFY Arg1:T24 Arg2:E12 T25 Disease_disorder 452 465 Blau syndrome E13 Disease_disorder:T25 T26 Disease_disorder 467 476 arthritis E14 Disease_disorder:T26 T27 Sign_symptom 481 485 rash E15 Sign_symptom:T27 R11 MODIFY Arg1:E13 Arg2:E14 R12 MODIFY Arg1:E13 Arg2:E15 T28 Duration 496 505 over time E16 Duration:T28 T29 Detailed_description 487 495 subsided R13 MODIFY Arg1:T29 Arg2:E15 R14 MODIFY Arg1:T29 Arg2:E14 A2 TREND E15 DEC A3 TREND E14 DEC T30 Disease_disorder 517 527 panuveitis E17 Disease_disorder:T30 T31 Detailed_description 507 516 Bilateral R15 MODIFY Arg1:T31 Arg2:E17 T33 Medication 589 601 methotrexate E18 Medication:T33 T34 Detailed_description 528 538 progressed R16 MODIFY Arg1:T34 Arg2:E17 T35 Disease_disorder 619 631 inflammation E19 Disease_disorder:T35 T36 Biological_structure 612 618 ocular R17 MODIFY Arg1:T36 Arg2:E19 T37 Detailed_description 632 641 persisted R18 MODIFY Arg1:T37 Arg2:E19 T38 Medication 672 679 steroid E20 Medication:T38 T39 Administration 680 690 injections T40 Detailed_description 666 671 local R19 MODIFY Arg1:T40 Arg2:T39 R20 MODIFY Arg1:T39 Arg2:E20 T41 Medication 727 755 methylprednisolone treatment E21 Medication:T41 T42 Administration 704 715;721 726 intravenous bolus T43 Administration 716 726 (IV) bolus R21 IDENTICAL Arg1:T43 Arg2:T42 R22 MODIFY Arg1:T43 Arg2:E21 T44 Detailed_description 695 703 repeated R23 MODIFY Arg1:T44 Arg2:T42 * OVERLAP E20 E21 E19 E18 T46 Medication 803 813 infliximab E22 Medication:T46 T47 Dosage 828 835;861 879 5 mg/kg every 4 to 6 weeks T48 Dosage 849 857;861 879 10 mg/kg every 4 to 6 weeks T50 Administration 858 860 IV R24 MODIFY Arg1:T47 Arg2:E22 R25 MODIFY Arg1:T48 Arg2:E22 R26 MODIFY Arg1:T50 Arg2:E22 T51 Date 939 978 1 year after this treatment was started E23 Date:T51 T52 Disease_disorder 979 986 uveitis E24 Disease_disorder:T52 T53 Severity 987 995 worsened R28 MODIFY Arg1:T53 Arg2:E24 T55 Medication 1017 1027 infliximab E25 Medication:T55 A4 TREND E25 DEC T56 Detailed_description 1032 1044 discontinued R29 MODIFY Arg1:T56 Arg2:E25 T57 Medication 1046 1056 Adalimumab E26 Medication:T57 T58 Dosage 1058 1080 24 mg/m2 every 2 weeks R30 MODIFY Arg1:T58 Arg2:E26 T60 Medication 1119 1131 methotrexate E27 Medication:T60 T61 Dosage 1133 1148 15 mg/m2/weekly R32 MODIFY Arg1:T61 Arg2:E27 A5 TREND E27 INC T49 Lab_value 1154 1163 increased R27 MODIFY Arg1:T49 Arg2:E27 T59 Disease_disorder 1174 1188 ocular disease E28 Disease_disorder:T59 T62 Detailed_description 1198 1204 active R31 MODIFY Arg1:T62 Arg2:E28 T63 Medication 1206 1227 Mycophenolate mofetil E29 Medication:T63 T64 Dosage 1229 1238 750 mg/m2 T65 Medication 1249 1258 abatacept E30 Medication:T65 T66 Dosage 1260 1274 10 mg/kg/month T67 Administration 1275 1277 IV R33 MODIFY Arg1:T66 Arg2:E30 R34 MODIFY Arg1:T67 Arg2:E30 R35 MODIFY Arg1:T64 Arg2:E29 T70 Disease_disorder 1404 1411 lesions E32 Disease_disorder:T70 T71 Biological_structure 1396 1403 retinal T72 Disease_disorder 1382 1395 granulomatous E33 Disease_disorder:T72 T73 Disease_disorder 1433 1445 inflammation E34 Disease_disorder:T73 T74 Biological_structure 1416 1432 anterior chamber R36 MODIFY Arg1:T74 Arg2:E34 T76 Medication 1551 1579 corticosteroid pulse therapy E36 Medication:T76 T77 Dosage 1640 1655 3 boluses/month T78 Duration 1660 1680 6 consecutive months E37 Duration:T78 T79 Medication 1819 1830 canakinumab E38 Medication:T79 T80 Dosage 1802 1815 2 mg/kg/month R37 MODIFY Arg1:T80 Arg2:E38 T81 Lab_value 1626 1639 an average of R38 MODIFY Arg1:T81 Arg2:T77 R39 MODIFY Arg1:T77 Arg2:E36 * OVERLAP E36 E37 E35 E52 T75 Medication 1772 1800 IL-1 antibody administration E35 Medication:T75 R40 SUB_PROCEDURE Arg1:E38 Arg2:E35 T82 Disease_disorder 1871 1883 ocular flare E39 Disease_disorder:T82 A7 POLARITY E39 NEG T84 Medication 1900 1921 steroid pulse therapy E41 Medication:T84 A8 POLARITY E41 NEG T83 Medication 1969 1981 methotrexate E40 Medication:T83 T85 Administration 1964 1968 oral R41 MODIFY Arg1:T85 Arg2:E40 T86 Medication 1995 2005 prednisone E42 Medication:T86 T87 Dosage 2007 2020 0.2 mg/kg/day T88 Lab_value 1986 1994 low-dose R42 MODIFY Arg1:T88 Arg2:E42 R43 MODIFY Arg1:T87 Arg2:E42 A9 TREND E40 STAY A10 TREND E42 STAY T89 Diagnostic_procedure 2057 2072 fluorangiograms E43 Diagnostic_procedure:T89 T91 Detailed_description 2137 2172 well tolerated with no side effects T92 Diagnostic_procedure 2190 2206 laboratory tests E44 Diagnostic_procedure:T92 T93 Frequency 2218 2225 monthly T94 Detailed_description 2232 2238 normal R44 MODIFY Arg1:T94 Arg2:E44 R45 MODIFY Arg1:T93 Arg2:E44 T95 Medication 2124 2132 The drug E45 Medication:T95 #1 AnnotatorNotes E45 Likely a coreference, but unclear which drug it's referring to. R46 MODIFY Arg1:T91 Arg2:E45 * OVERLAP E45 E44 E39 E41 E38 E40 E42 E43 R47 MODIFY Arg1:E2 Arg2:E1 R48 MODIFY Arg1:E3 Arg2:E1 R49 MODIFY Arg1:E4 Arg2:E1 R50 MODIFY Arg1:E5 Arg2:E1 * OVERLAP E4 E5 E2 E3 E46 T90 Diagnostic_procedure 206 216 histologic E46 Diagnostic_procedure:T90 R51 MODIFY Arg1:E6 Arg2:E46 R52 MODIFY Arg1:E46 Arg2:E1 R53 MODIFY Arg1:E7 Arg2:E1 * OVERLAP E6 E7 * OVERLAP E8 E12 R54 BEFORE Arg1:E9 Arg2:E10 * OVERLAP E10 E11 E15 E16 E14 T96 Date 789 801 age 10 years E47 Date:T96 T97 Date 545 556 age 5 years E48 Date:T97 R55 AFTER Arg1:E17 Arg2:E48 R56 BEFORE Arg1:E48 Arg2:E18 R57 BEFORE Arg1:E21 Arg2:E47 * OVERLAP E47 E22 R58 BEFORE Arg1:E22 Arg2:E23 R59 BEFORE Arg1:E16 Arg2:E17 * OVERLAP E23 E24 T98 Date 1004 1010 age 12 E49 Date:T98 R60 BEFORE Arg1:E24 Arg2:E49 * OVERLAP E49 E25 R61 BEFORE Arg1:E25 Arg2:E26 * OVERLAP E26 E27 E28 R62 BEFORE Arg1:E28 Arg2:E29 R63 BEFORE Arg1:E29 Arg2:E30 T68 Diagnostic_procedure 1311 1342 without significant improvement E31 Diagnostic_procedure:T68 A6 TREND E31 STAY R64 BEFORE Arg1:E30 Arg2:E31 T99 Date 1347 1359 age 16 years E50 Date:T99 R65 BEFORE Arg1:E31 Arg2:E50 R66 MODIFY Arg1:T71 Arg2:E32 R67 MODIFY Arg1:E33 Arg2:E32 * OVERLAP E50 E32 E34 E51 T100 Sign_symptom 1459 1464 edema E51 Sign_symptom:T100 T101 Biological_structure 1451 1458 macular R68 MODIFY Arg1:T101 Arg2:E51 T102 Disease_disorder 1489 1507 retinal detachment E52 Disease_disorder:T102 R69 BEFORE Arg1:E51 Arg2:E52